Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.56 |
| ▸ | SLC2A3 | P11169 | 9/20 | 0.56 |
| ▸ | SLC2A2 | P11168 | 4/20 | 0.53 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343612 | 0.92 | SLC2A1 (0.48) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25343109 | 0.88 | SLC2A1 (0.45) | SLC2A1SLC2A3SLC2A2MAPTLMNA | |
| SCHEMBL25343885 | 0.88 | PIP4K2A (0.54) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25341819 | 0.86 | SLC2A1 (0.42) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25344441 | 0.86 | SLC2A1 (0.42) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25344401 | 0.85 | SLC2A1 (0.47) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL30568427 | 0.85 | SLC2A1 (0.45) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25344574 | 0.85 | SLC2A1 (0.45) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25977132 | 0.85 | SLC2A1 (0.42) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT | |
| SCHEMBL25344672 | 0.85 | SLC2A1 (0.45) | SLC2A1SLC2A3SLC2A2PIP4K2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4536662-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025012057-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| CN-119212995-A | Indazole macrocycles for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023237457-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237457-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | MALT1, CCR1, CCR6 | SLC2A1 3252/4885SLC2A3 3890/4885SLC2A2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.